Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 12Bevacizumab 8Carboplatin 6Radiotherapy 5Erlotinib Hydrochloride 5temsirolimus 3Surgical Procedures, Operative 3Irinotecan 3IL13-PE38 3veliparib 2pembrolizumab 2etoposide phosphate 2Vorinostat 2Specimen Handling 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Radiation 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Genetic Therapy 2Everolimus 2Cetuximab 2Carmustine 2Cancer Vaccines 2trastuzumab deruxtecan 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sonidegib 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Astrocytoma × Eflornithine × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡